DUBLIN, July 31, 2020 /PRNewswire/ -- The "Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The 'Cell Reprogramming (iPSC Generation)/Direct Reprogramming Services and Products Market, 2020-2030' report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

In addition to other elements, the study includes:

One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030.

The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. CURRENT MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Allele Biotechnology 6.3. ALSTEM 6.4. Applied Biological Materials 6.5. Axol Bioscience 6.6. Creative Bioarray 6.7. DefiniGEN 6.8. FUJIFILM Cellular Dynamics International 6.9. Lonza 6.10. Mogrify 6.11. REPROCELL 6.12. Stemnovate 6.13. Thermo fisher Scientific

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

8. PARTNERSHIPS AND COLLABORATIONS

9. LIKELY PARTNERSHIP OPPORTUNITIES

10. MARKET FORECAST

11. EXECUTIVE INSIGHTS

12. CONCLUDING REMARKS

For more information about this report visit https://www.researchandmarkets.com/r/dywciv

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

See original here:
Global Outlook for Cell Reprogramming and Direct Reprogramming Services and Products Market to 2030, with Company Profiles of Leading Players...